Publication

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Journal Paper/Review - Dec 7, 2021

Units
PubMed
Doi
Contact

Citation
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
Type
Journal Paper/Review (English)
Journal
J Cancer Res Clin Oncol 2021; 148
Publication Date
Dec 7, 2021
Issn Electronic
1432-1335
Pages
647-656
Brief description/objective

Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are barely known. We investigated the association of preexisting autoantibodies in the development of ICI-induced hepatitis in a prospective cohort of cancer patients.